THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Benjamin Scherlag to Anti-Arrhythmia Agents

This is a "connection" page, showing publications Benjamin Scherlag has written about Anti-Arrhythmia Agents.
Connection Strength

2.030
  1. When nerves go awry: The multiple ways to treat atrial fibrillation. Heart Rhythm. 2016 11; 13(11):2118.
    View in: PubMed
    Score: 0.511
  2. Atrial fibrillation in obstructive sleep apnea: Neural mechanisms and emerging therapies. Trends Cardiovasc Med. 2021 02; 31(2):127-132.
    View in: PubMed
    Score: 0.163
  3. Slow antegrade excitation and delayed retrograde activation through an "inexcitable zone": A basis for arrhythmia formation in infarcted myocardium ex vivo. J Cardiovasc Electrophysiol. 2017 Oct; 28(10):1213-1222.
    View in: PubMed
    Score: 0.136
  4. Acetylcholine-Atropine Interactions: Paradoxical Effects on Atrial Fibrillation Inducibility. J Cardiovasc Pharmacol. 2017 Jun; 69(6):369-373.
    View in: PubMed
    Score: 0.136
  5. Antiarrhythmic effects of vasostatin-1 in a canine model of atrial fibrillation. J Cardiovasc Electrophysiol. 2012 Jul; 23(7):771-7.
    View in: PubMed
    Score: 0.095
  6. Pharmacological prevention and termination of focal atrial fibrillation. Europace. 2012 Mar; 14(3):426-30.
    View in: PubMed
    Score: 0.092
  7. Non-pharmacological, non-ablative approaches for the treatment of atrial fibrillation: experimental evidence and potential clinical implications. J Cardiovasc Transl Res. 2011 Feb; 4(1):35-41.
    View in: PubMed
    Score: 0.086
  8. Electrophysiologic actions of d,l-sotalol and GLG-V-13 in ischemically injured canine epicardium. J Cardiovasc Pharmacol. 2007 Sep; 50(3):304-13.
    View in: PubMed
    Score: 0.069
  9. Treatment of arrhythmias by blocking slow current. Ann Intern Med. 1980 Dec; 93(6):919-21.
    View in: PubMed
    Score: 0.043
  10. The acute and subchronic toxicity of BRB-I-28, a novel class Ib antiarrhythmic agent, in CD-1 mice. Food Chem Toxicol. 2000 Sep; 38(9):817-23.
    View in: PubMed
    Score: 0.043
  11. Effect of GLG-V-13, a class III antiarrhythmic agent, on potassium currents in rabbit ventricular myocytes. Life Sci. 2000 Mar; 66(17):PL 253-8.
    View in: PubMed
    Score: 0.041
  12. Preliminary acute and subchronic toxicity studies of GLG-V-13, a novel class III antiarrhythmic agent, in mice. Arzneimittelforschung. 2000 Jan; 50(1):31-8.
    View in: PubMed
    Score: 0.041
  13. Facilitation of epinephrine-induced afterdepolarizations by class III antiarrhythmic drugs. J Electrocardiol. 1997 Jul; 30(3):217-24.
    View in: PubMed
    Score: 0.034
  14. Early afterdepolarizations produced by d,l-sotalol and clofilium. J Cardiovasc Electrophysiol. 1997 Jun; 8(6):667-78.
    View in: PubMed
    Score: 0.034
  15. Class III electrophysiologic actions of imidazole-substituted diheterabicyclononanes in canine myocardium. J Pharmacol Exp Ther. 1997 Apr; 281(1):155-62.
    View in: PubMed
    Score: 0.034
  16. Electrophysiological and inotropic characterization of a novel class III antiarrhythmic agent, GLG-V-13, in the mammalian heart. J Cardiovasc Pharmacol. 1996 Aug; 28(2):182-91.
    View in: PubMed
    Score: 0.032
  17. Novel 3,7-diheterabicyclo[3.3.1]nonanes that possess predominant class III antiarrhythmic activity in 1-4 day post infarction dog models: X-ray diffraction analysis of 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3,7-diazabicyclo[3.3.1]nona ne dihydroperchlorate. J Med Chem. 1996 Jun 21; 39(13):2559-70.
    View in: PubMed
    Score: 0.032
  18. Pharmacokinetics and plasma protein binding of the new potent class III antiarrhythmic agent 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3, 7-diazabicyclo[3.3.1]nonane dihydroperchlorate. Arzneimittelforschung. 1995 Jun; 45(6):670-5.
    View in: PubMed
    Score: 0.030
  19. Electrophysiological characterization of a novel class III antiarrhythmic agent, GLG-V-13 in the mammalian heart. Acta Physiol Hung. 1995; 83(1):13-30.
    View in: PubMed
    Score: 0.029
  20. The efficacy of antiarrhythmic agents during acute myocardial ischemia and the role of heart rate. Circulation. 1974 Sep; 50(3):507-14.
    View in: PubMed
    Score: 0.028
  21. Effects of novel antiarrhythmic agents, BRB-I-28 and its derivatives, on the heart mitochondrial respiratory chain and sarcoplasmic reticulum Ca(2+)-ATPase. Res Commun Mol Pathol Pharmacol. 1994 Aug; 85(2):193-208.
    View in: PubMed
    Score: 0.028
  22. Effects of disopyramide on electrophysiological and mechanical properties of the heart. J Pharm Sci. 1973 Dec; 62(12):1924-9.
    View in: PubMed
    Score: 0.027
  23. Electrophysiologic actions of BRB-I-28 in ischemically injured canine myocardium. J Cardiovasc Pharmacol. 1993 Apr; 21(4):637-46.
    View in: PubMed
    Score: 0.025
  24. The comparative antiarrhythmic and proarrhythmic activity of a 3,7-diheterobicyclo[3.3.1]nonane, BRB-I-28, and lidocaine in the 1-4-day-old infarcted dog heart. Acta Physiol Hung. 1993; 81(3):289-99.
    View in: PubMed
    Score: 0.025
  25. High-performance liquid chromatographic determination of BRB-I-28, a novel antiarrhythmic agent, in dog plasma and urine. J Chromatogr. 1992 Dec 02; 583(2):274-9.
    View in: PubMed
    Score: 0.025
  26. Effects of BRB-I-28, a novel antiarrhythmic agent, and its derivatives on cardiac Na+,K(+)-ATPase, Mg(2+)-ATPase activities and contractile force. Res Commun Chem Pathol Pharmacol. 1992 Oct; 78(1):3-16.
    View in: PubMed
    Score: 0.025
  27. Electrophysiologic actions of clofilium and lidocaine in ischemically injured canine epicardium. J Pharmacol Exp Ther. 1992 Jul; 262(1):375-82.
    View in: PubMed
    Score: 0.024
  28. The cardiovascular and antiarrhythmic properties of a series of novel sparteine analogs. Proc West Pharmacol Soc. 1992; 35:87-91.
    View in: PubMed
    Score: 0.023
  29. Electrophysiological actions of BRB-I-28 in canine myocardial tissues. J Pharmacol Exp Ther. 1991 Nov; 259(2):558-65.
    View in: PubMed
    Score: 0.023
  30. An acute experimental model demonstrating 2 different forms of sustained atrial tachyarrhythmias. Circ Arrhythm Electrophysiol. 2009 Aug; 2(4):384-92.
    View in: PubMed
    Score: 0.019
  31. Antifibrillatory actions of cisatracurium: an atrial specific M2 receptor antagonist. J Cardiovasc Electrophysiol. 2008 Aug; 19(8):861-8.
    View in: PubMed
    Score: 0.018
  32. Synthesis, conformational analysis, and antiarrhythmic properties of 7-benzyl-3-thia-7-azabicyclo[3.3.1]nonan-9-one, 7-benzyl-3-thia-7-azabicyclo[3.3.1]nonane hydroperchlorate, and 7-benzyl-9-phenyl-3-thia-7-azabicyclo[3.3.1]nonan-9-ol hydroperchlorate and derivatives: single-crystal X-ray diffraction analysis and evidence for chair-chair and chair-boat conformers in the solid state. J Med Chem. 1984 Jun; 27(6):758-67.
    View in: PubMed
    Score: 0.014
  33. Electrophysiologic basis for arrhythmias in ischemic heart disease. Am J Cardiol. 1984 Feb 27; 53(5):1B-7B.
    View in: PubMed
    Score: 0.014
  34. Direct endocardial recording from an accessory atrioventricular pathway: localization of the site of block, effect of antiarrhythmic drugs, and attempt at nonsurgical ablation. Circulation. 1983 Nov; 68(5):906-16.
    View in: PubMed
    Score: 0.013
  35. A technique for stable His-bundle recording and pacing: electrophysiological and hemodynamic correlates. Pacing Clin Electrophysiol. 1995 Oct; 18(10):1894-901.
    View in: PubMed
    Score: 0.008
  36. The monophasic action potential in clinical cardiology. Clin Cardiol. 1991 Jun; 14(6):505-10.
    View in: PubMed
    Score: 0.006
  37. Diphenylhydantoin prevention of arrhythmias in the digitalis-sensitized dog after direct-current cardioversion. Circulation. 1968 Mar; 37(3):424-8.
    View in: PubMed
    Score: 0.004
  38. Effect of diphenylhydantoin sodium (dilantin) on myocardial A-V potassium difference. Am J Physiol. 1968 Apr; 214(4):880-4.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES